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time, choice of validated patient reported outcome measures
(PRO) to assess and monitor ED, and opinion on how ED is
currently viewed. RESULTS: A total of 1658 congress delegates
participated in the study, of which 1590 met the inclusion crite-
ria. Sixty-one percent of the respondents prescribed a PDE5i as
the ﬁrst course of action when seeing an ED patient. Assessment
of contraindications or cardiovascular risk factors, physical
examination, blood pressure measurement, and laboratory tests
were rarely conducted as a ﬁrst course of action (1–3%, depend-
ing on the assessment/test). The most popular means of assessing
and monitoring ED status was via patient interview (68%), as
opposed to the use of validated PRO measures. Seventy-six
percent of respondents agreed that the large number of men
accessing ED medicines through uncontrolled sources repre-
sented a true medical issue and 81% agreed that actions to
reduce health risks associated with such uncontrolled access
to PDE5i were essential. CONCLUSIONS: While the EAU
guidelines recommend a diagnostic workup prior to prescribing
PDE5is, this study demonstrates that a majority of participating
respondents initiate PDE5i treatment in an ED patient initially
after a simple patient interview with no prior physical examina-
tion or diagnostic testing.
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OBJECTIVES: Dalbavancin is a new, once weekly, intravenous,
glycopeptide antibacterial. In phase III trial, dalbavancin demon-
strated comparable efﬁcacy versus linezolid in complicated skin
and soft tissue infections (cSSTIs). Teicoplanin is a key antimicro-
bial comparator in Europe, therefore an indirect comparison
based on available published efﬁcacy was performed in “all”
Staphylococcus aureus (SA) patients. A Bayesian meta-analysis
was conducted to compare success rates of antibacterials versus
teicoplanin in cSSTIs due to SA. METHODS: Medline, Embase,
andCochrane databaseswere searched to identify clinical trials on
dalbavancin, daptomycin, linezolid, telavancin, teicoplanin, tige-
cycline, and vancomycin in cSSTIs. Two independent reviewers
completed data extraction, study quality, and heterogeneity
assessment. Pooled efﬁcacy estimates were generated based on
clinical and microbiological success rates for the all SA cSSTI
patients. A random effects model was used with outcome pre-
dicted by medication and confounders of success deﬁnition,
dosing, age and gender. The impact of base case confounders, ﬁxed
vs random effects models and doses was investigated in sensitivity
analyses. RESULTS: Out of 36 articles, reporting on 11 trials,
6 treatments and 17 treatment arms (n = 955) were included.
Pooled success rate for teicoplanin was 88.6% (71.7;97.2) and
differences versus comparators for the base case analysis are:
vancomycin -9.4% (-47.1;15.5), linezolid +0.4% (-12.9;17.6),
tigecycline -6% (-9.7;17.7), dalbavancin +0.5% (-12.9;16.8),
and telavancin -5% (-43.7;21.5). Success rates for dalbavancin
and linezolid were numerically higher versus teicoplanin,
although differences were not signiﬁcant. These ﬁndings were
consistent in a variety of sensitivity analyses. CONCLUSIONS:
Dalbavancin demonstrated high microbiological success rates,
comparable to teicoplanin and other antimicrobials in SA cSSTI.
These data are consistent with the results of the phase III study
versus linezolid. In the context of the limited numbers of patients
available for some agents and the indirect nature of the compari-
son; further analyses are needed in this populations.
PIN2
ASSESSING ANTIMICROBIAL SUCCESS RATES INTHE
TREATMENT OF METHICILLIN-RESISTANT
STAPHYLOCOCCUS AUREUS (MRSA) COMPLICATED SKIN
AND SOFTTISSUE INFECTIONS (CSSTI):A BAYESIAN
META-ANALYSIS
Logman JFS1,Treur MJ1,Verheggen BG1, Heeg BMS1, Stephens JM2,
Haider S3, Cappelleri JC3, Nathwani D4,Tice A5,Van Hout BA1
1Pharmerit Europe, Rotterdam,The Netherlands, 2Pharmerit North
America LLC, Bethesda, MD, USA, 3Pﬁzer Inc, Groton, CT, USA,
4Ninewells Hospital & Medical School, Dundee, UK, 5University of
Hawaii, Honolulu, HI, USA
OBJECTIVES: To compare success rates of newer antimicrobial
agents to vancomycin for treatment of MRSA cSSTIs using a
Bayesian meta-analysis. METHODS: A systematic literature
review was conducted of Medline, Embase, and Cochrane data-
bases to identify clinical trials on dalbavancin, daptomycin, lin-
ezolid, telavancin, teicoplanin, tigecycline, and vancomycin in
cSSTIs. Data extraction, study quality, and heterogeneity assess-
ments were completed by two independent reviewers. Pooled
efﬁcacy estimates were generated based on clinical and micro-
biological success rates for the MRSA-subgroups in the cSSTI
clinical trials using a Bayesian approach. The base case used a
random effects model with outcome predicted by medication and
confounders of success deﬁnition, dosing, age and gender. Sensi-
tivity analyses included testing impact of base case confounders,
ﬁxed vs random effects models, article quality, and difference in
success deﬁnition. RESULTS: Of 35 initially identiﬁed studies, 14
trials on six treatments with 28 treatment arms (n = 1840) met
the inclusion criteria for the MRSA subpopulation and were
included in the analysis. No MRSA-speciﬁc data were reported
for teicoplanin, thus it was not included. MRSA-conﬁrmed cSSTI
pooled success rates and 95% credible intervals for the base case
analysis were: vancomycin 74.7% (64.1–83.5%), linezolid
84.4% (76.6–90.6%), daptomycin 78.1% (54.6–93.2%), tigecy-
cline 70.4% (48.0–87.6%), dalbavancin 87.7% (74.6–95.4%),
and telavancin 83.5% (73.6–90.8%). The estimated difference
with vancomycin was signiﬁcant for dalbavancin, linezolid and
telavancin. The ﬁnding of lower vancomycin efﬁcacy in MRSA
cSSTI was consistent in a variety of sensitivity analyses, indicat-
ing the results were robust. CONCLUSIONS: This meta-analysis
suggests higher success rates for the novel glycopeptides and
linezolid in the treatment of MRSA-conﬁrmed cSSTIs. The uncer-
tainty margins reﬂect the limited numbers of patients available
for some agents and the indirect nature of the treatment com-
parisons. Further evidence from randomized clinical trials is
needed to more deﬁnitively establish the value of the newer
antimicrobials in MRSA cSSTIs.
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OBJECTIVES: To forecast through computer simulation the
effectiveness of medical intervention strategies in reducing the
A428 Abstracts
